611
611 is a pharmaceutical drug with 7 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
1
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
4
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
Clinical Trials (7)
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7